Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multi-platform satellite-derived products during the 2025 Etna eruption.

Scientific data·2025
Same author

Observation of WZγ Production in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2024
Same author

Search for Dark Photons in Rare Z Boson Decays with the ATLAS Detector.

Physical review letters·2024
Same author

Observation of Single-Top-Quark Production in Association with a Photon Using the ATLAS Detector.

Physical review letters·2023
Same author

Measurement of Suppression of Large-Radius Jets and Its Dependence on Substructure in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2023
Same author

Measurement of the Sensitivity of Two-Particle Correlations in pp Collisions to the Presence of Hard Scatterings.

Physical review letters·2023

Related Experiment Video

Updated: Jun 24, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Pomegranate fruit components modulate human thrombin.

M Cuccioloni1, M Mozzicafreddo, L Sparapani

  • 1Department of Molecular, Cellular & Animal Biology, University of Camerino, Italy.

Fitoterapia
|April 11, 2009
PubMed
Summary
This summary is machine-generated.

Pomegranate fruit components, rich in ellagic acid, were analyzed for bioactive metabolites. These components show potential in regulating physio-pathological processes involving thrombin (or thrombin-like proteinase).

More Related Videos

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Related Experiment Videos

Last Updated: Jun 24, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

Area of Science:

  • Pharmacognosy and Phytochemistry
  • Biochemistry and Molecular Biology

Background:

  • Pomegranate (Punica granatum) is recognized for its rich polyphenol content and significant antioxidant properties.
  • Understanding the specific bioactive compounds within different pomegranate fruit parts is crucial for exploring its health benefits.

Purpose of the Study:

  • To characterize the monomeric phenolic compounds present in isolated pomegranate fruit components: endocarp, mesocarp, and aril.
  • To investigate the impact of these pomegranate fruit components on the amidolytic activity of human thrombin.

Main Methods:

  • Isolation and characterization of phenolic compounds from distinct pomegranate fruit parts (endocarp, mesocarp, aril).
  • Assay of human thrombin amidolytic activity in the presence of pomegranate fruit component extracts.

Main Results:

  • Identification of varied monomeric phenolic profiles across the endocarp, mesocarp, and aril.
  • Pomegranate components were found to contain bioactive metabolites, notably ellagic acid.
  • A significant effect of pomegranate fruit components on human thrombin amidolytic activity was observed.

Conclusions:

  • Pomegranate fruit components harbor bioactive metabolites, with ellagic acid being a key compound.
  • The study suggests a potential role for pomegranate extract in modulating thrombin activity.
  • These findings indicate a possible application of pomegranate in managing physio-pathological conditions involving thrombin or thrombin-like proteinases.